BR016

BR016 is a preclinical-stage recombinant protein biologic being developed by Wuhan Binhui Biotechnology. Positioned within the company's oncology pipeline, BR016 represents an expansion into protein-based therapeutics alongside Binhui's established oncolytic virus platform. While specific molecular targets and detailed mechanisms of action have not been publicly disclosed, the asset is currently undergoing laboratory and animal studies to evaluate its safety and efficacy profile for potential cancer treatment. As of late 2024, it remains in the early stages of development, with the developer focusing on its potential to modulate immune responses or directly target tumor cells.